These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 22188815)
1. Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Bid HK; Zhan J; Phelps DA; Kurmasheva RT; Houghton PJ Mol Cancer Ther; 2012 Mar; 11(3):649-59. PubMed ID: 22188815 [TBL] [Abstract][Full Text] [Related]
2. Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy. Bid HK; London CA; Gao J; Zhong H; Hollingsworth RE; Fernandez S; Mo X; Houghton PJ Clin Cancer Res; 2013 Jun; 19(11):2984-94. PubMed ID: 23549869 [TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling. Huang SW; Lien JC; Kuo SC; Huang TF Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611 [TBL] [Abstract][Full Text] [Related]
4. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339 [TBL] [Abstract][Full Text] [Related]
5. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506 [TBL] [Abstract][Full Text] [Related]
6. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Gao F; Vasquez SX; Su F; Roberts S; Shah N; Grijalva V; Imaizumi S; Chattopadhyay A; Ganapathy E; Meriwether D; Johnston B; Anantharamaiah GM; Navab M; Fogelman AM; Reddy ST; Farias-Eisner R Integr Biol (Camb); 2011 Apr; 3(4):479-89. PubMed ID: 21283904 [TBL] [Abstract][Full Text] [Related]
7. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627 [TBL] [Abstract][Full Text] [Related]
9. NADPH oxidase 4 mediates insulin-stimulated HIF-1α and VEGF expression, and angiogenesis in vitro. Meng D; Mei A; Liu J; Kang X; Shi X; Qian R; Chen S PLoS One; 2012; 7(10):e48393. PubMed ID: 23144758 [TBL] [Abstract][Full Text] [Related]
10. The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression. Park MS; Kim BR; Dong SM; Lee SH; Kim DY; Rho SB Oncotarget; 2014 Jul; 5(13):4935-44. PubMed ID: 24952732 [TBL] [Abstract][Full Text] [Related]
11. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis. Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414 [TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183 [TBL] [Abstract][Full Text] [Related]
13. Endothelium-derived nitric oxide (NO) activates the NO-epidermal growth factor receptor-mediated signaling pathway in bradykinin-stimulated angiogenesis. Moraes MS; Costa PE; Batista WL; Paschoalin T; Curcio MF; Borges RE; Taha MO; Fonseca FV; Stern A; Monteiro HP Arch Biochem Biophys; 2014 Sep; 558():14-27. PubMed ID: 24960080 [TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. Bid HK; Oswald D; Li C; London CA; Lin J; Houghton PJ PLoS One; 2012; 7(4):e35513. PubMed ID: 22530037 [TBL] [Abstract][Full Text] [Related]
15. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM MAbs; 2011; 3(3):273-88. PubMed ID: 21393993 [TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic Potential of Microbial Metabolite Elaiophylin for Targeting Tumor Angiogenesis. Lim HN; Jang JP; Han JM; Jang JH; Ahn JS; Jung HJ Molecules; 2018 Mar; 23(3):. PubMed ID: 29498688 [TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799 [TBL] [Abstract][Full Text] [Related]
18. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention. Bhat TA; Nambiar D; Pal A; Agarwal R; Singh RP Carcinogenesis; 2012 Feb; 33(2):385-93. PubMed ID: 22139440 [TBL] [Abstract][Full Text] [Related]
19. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling. Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875 [TBL] [Abstract][Full Text] [Related]
20. A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF. Sato S; Drake AW; Tsuji I; Fan J PLoS One; 2012; 7(12):e51964. PubMed ID: 23251664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]